In an exclusive video interview with PropThink.com, Michael Bailey, Chief Commercial Officer of AVEO Pharmaceuticals AVEO, explains the benefits of AVEO's Phase III drug candidate Tivozanib in renal cell carcinoma, citing lower toxicity than existing drugs and extended progression-free survival (PFS). Bailey also discusses the company's current partnerships with Astellas Pharma ALPMY and Biogen Idec BIIB in developing two of their three pipeline compounds and talks about AVEO's filing expectations for Q3 2012 and strategy entering the next year of commercialization.
Click here to view the exclusive video interview with AVEO Pharmaceuticals.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PropThink via Thomson Reuters ONE
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
